Revealing Public Opinion towards the COVID-19 Vaccine with Weibo Data in China: BertFDA-Based Model

利用微博数据揭示中国公众对新冠疫苗的看法:基于BERTFDA的模型

阅读:1

Abstract

The COVID-19 pandemic has created unprecedented burdens on people's health and subjective well-being. While countries around the world have established models to track and predict the affective states of COVID-19, identifying the topics of public discussion and sentiment evolution of the vaccine, particularly the differences in topics of concern between vaccine-support and vaccine-hesitant groups, remains scarce. Using social media data from the two years following the outbreak of COVID-19 (23 January 2020 to 23 January 2022), coupled with state-of-the-art natural language processing (NLP) techniques, we developed a public opinion analysis framework (BertFDA). First, using dynamic topic clustering on Weibo through the latent Dirichlet allocation (LDA) model, a total of 118 topics were generated in 24 months using 2,211,806 microblog posts. Second, by building an improved Bert pre-training model for sentiment classification, we provide evidence that public negative sentiment continued to decline in the early stages of COVID-19 vaccination. Third, by modeling and analyzing the microblog posts from the vaccine-support group and the vaccine-hesitant group, we discover that the vaccine-support group was more concerned about vaccine effectiveness and the reporting of news, reflecting greater group cohesion, whereas the vaccine-hesitant group was particularly concerned about the spread of coronavirus variants and vaccine side effects. Finally, we deployed different machine learning models to predict public opinion. Moreover, functional data analysis (FDA) is developed to build the functional sentiment curve, which can effectively capture the dynamic changes with the explicit function. This study can aid governments in developing effective interventions and education campaigns to boost vaccination rates.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。